Skip to main content
. 2022 Nov 11;15:2437–2443. doi: 10.2147/CCID.S391944

Table 1.

Summary of Patients’ Characteristics

Patient Sex Age AD of Duration (Years) Visible Areas Comorbidities EASI (W0/8/16) BSA%(W0/8/16) Serum IgE (IU/L) Patch Test Adverse Event
1 M 67 1 Face, Hands, Torso, Leg - 37.4/22.6/16.7 23/18/10 1004 - -
2 M 29 3 Face, Hands, Torso - 23.8/15.7/11.7 18/13/9 - - Head and Neck Dermatitis
3 F 40 5 Face, Hands, Torso, Leg AR 13.2/9.6/5.3 12/10/6 - - -
4 M 15 14 Face, Hands, Torso, Leg AR 14.8/7.2/5.1 12/6/5 >2000 - -
5 M 11 4 Face, Torso, Leg - 22.5/16.3/9.8 19/13/6 - + -
6 M 7 5 Face, Torso, Leg - 18.3/12.6/4 15/9/5 436 -
7 M 5 5 Face, Hands, Torso, Leg AR 38.7/22.4/13.7 22/14/7 >2000 + -
8 M 7 5 Face, Hands, Torso, Leg AS, AR 16.6/10.7/4.3 13/7/5 855 - -
9 M 9 6 Face, Hands, Torso, Leg AK 19/13.5/4.8 21/11/7 797 - -
10 F 8 7 Face, Torso - 16.8/12.4/9.8 12/7/6 - - -

Abbreviations: M, male; F, female; AR, allergic rhinitis; AK, allergic keratoconjunctivitis; AS, asthma; T0, baseline; T4, 16 weeks after induction; IGA, investigator’s global assessment; EASI, eczema area, and severity index score;-, none.